Key Takeaways
- Genentech plans to invest $2 billion in a new manufacturing facility in Holly Springs, creating an estimated 520 jobs.
- The facility is expected to be operational by the end of 2029 and will focus on obesity drug production.
- Genentech’s investment highlights North Carolina’s growing role in the biotech industry, attracting major companies like Amgen and Novo Nordisk.
Expansion of Genentech’s Facility
Genentech, a biotechnology company based in San Francisco and a subsidiary of Roche, has expanded its plans for a new manufacturing facility in Holly Springs, North Carolina. The company announced on Tuesday that it will invest approximately $2 billion in the project, significantly higher than the initial $700 million investment disclosed in March. This ambitious expansion is expected to create jobs for an additional 100 workers, bringing the total to about 520.
“This expansion reflects our long-term commitment to the United States and communities like Holly Springs,” said CEO Ashley Magargee. The new manufacturing plant will become the company’s first on the East Coast, supporting the development of obesity medication.
The facility is planned to encompass 700,000 square feet and is targeted to begin operations by the end of 2029. This move comes as several major biotech firms, including Amgen and FujiFilm Diosynth, also ramp up manufacturing efforts in Holly Springs, establishing the town as a burgeoning biotech hub.
Governor Josh Stein praised the investment, indicating that it would create durable jobs and bolster North Carolina’s life sciences sector. State and local officials have previously approved an incentives package for Genentech, potentially amounting to $13.1 million, contingent on meeting hiring and investment benchmarks over the next 12 years. This project is anticipated to contribute an estimated $3.1 billion to the state’s economy.
The average salary for Genentech’s new jobs is projected to be around $120,000, compared to the average private sector wage in Wake County. Additionally, between 2028 and 2032, the company plans to hire a total of 420 employees as part of this venture.
North Carolina has become a magnet for life sciences companies, with over 800 businesses in the sector and another 2,500 supporting them. The state shipped nearly $13 billion in pharmaceutical products in 2024, appealing to firms due to its affordability in relation to other biotech hubs.
Genentech’s choice to expand in Holly Springs is attributed to several factors, including the availability of a skilled workforce, proximity to prominent research universities, and ongoing infrastructure improvements. Local and state incentives continue to draw major players to the region, indicating a expanding presence in biotech manufacturing in North Carolina.
The content above is a summary. For more details, see the source article.